Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies

Leukemia. 2022 Apr;36(4):1164-1166. doi: 10.1038/s41375-022-01509-0. Epub 2022 Jan 20.

Noam E Kopmar¹, Megan Othus², Kelda M Gardner³, Carole Shaw⁴, Anna B Halpern^{3

4}, Bart L Scott^{4

5}, Paul C Hendrie^{3

4}, Roland B Walter^{3

4

6

7}, Pamela S Becker^{3

4}, Elihu H Estey^{3

4}, Mary-Elizabeth M Percival^{8

9}

¹ Hematology and Oncology Fellowship Program, University of Washington, Seattle, WA, USA.
² Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
³ Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
⁴ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁵ Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA.
⁶ Department of Pathology, University of Washington, Seattle, WA, USA.
⁷ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁸ Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. [email protected].
⁹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. [email protected].

No abstract available

Publication types